Ocugen
Clinical trials sponsored by Ocugen, explained in plain language.
Biotech developing gene therapies and vaccines for eye diseases and COVID-19.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Gene therapy slows vision loss in stargardt disease trial Results expected Sep 2026 (estimated) May already have reported ↗ 🚀 Make-or-break
- Gene therapy trial aims to restore night vision in rare eye disease Results expected Feb 2027 (estimated) May already have reported ↗ 🚀 Make-or-break
- Can a single eye injection restore sight in genetic blindness? Results expected Mar 2027 (estimated)
-
Last-Chance access: experimental eye treatment opens for 75 RP patients
Disease control Expanded accessThis program offers an experimental treatment called OCU400 to up to 75 adults with retinitis pigmentosa (RP) who cannot join the main Phase 3 study. Participants must be 18 or older, have a confirmed genetic diagnosis of RP (except a specific mutation), and have remaining light-…
Sponsor: Ocugen • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can a One-Time gene therapy stop the march of dry AMD?
Disease control Recruiting nowThis phase 3 trial tests whether a single injection of OCU410, a gene therapy, can slow the growth of geographic atrophy—an advanced form of dry age-related macular degeneration that causes blind spots. About 237 adults aged 55 and older with the condition will be randomly assign…
Phase 3 • Sponsor: Ocugen • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New eye injection aims to save sight in diabetes patients
Disease control Recruiting nowThis early-stage trial tests a new drug called OCU200, given as an injection into the eye, for people with diabetic macular edema (swelling in the center of the retina caused by diabetes). The study will include 24 participants and will primarily check for safety and side effects…
Phase 1 • Sponsor: Ocugen • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC